Salarius Pharmaceuticals (NASDAQ:SLRX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Friday, Zacks.com reports. According to Zacks, “Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company’s lead candidate is Seclidemstat, which is […]
Equities Research Analysts’ downgrades for Thursday, April 21st: Alcoa (NYSE:AA) was downgraded by analysts at Citigroup Inc. from a buy rating to a neutral rating. They currently have $84.00 price target on the stock. Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by analysts at Citigroup Inc. from a buy rating to a neutral rating. The firm currently […]
Zacks Investment Research downgraded shares of Salarius Pharmaceuticals (NASDAQ:SLRX – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company’s lead candidate is […]